Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ALN-TTR02 in familial amyloidotic polyneuropathy
2013-001644-65Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- May 2013
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patisiran in transthyretin amyloidosis (ATTR), familial amyloid polyneuropathy (FAP) and amyloid cardiomyopathy, sponsored by Alnylam Pharmaceuticals. Primary endpoint: Long-term safety and tolerability of ALN-TTR02. Started May 2013; status: completed.
02
Drugs
patisiran
03
Conditions
transthyretin amyloidosis (ATTR)familial amyloid polyneuropathy (FAP)amyloid cardiomyopathy
Beyond the preview
Go deeper on 2013-001644-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001644-65.